Long-term response to subcutaneous treprostinil
| Lang [14] | Barst [13] | |
| Drug | Treprostinil | Treprostinil |
| Design | 3-yr, multicentre, retrospective analysis | 4-yr, multicentre, retrospective analysis; other PAH therapies added as needed |
| Patients | 99 PAH, 23 CTEPH | 860 PAH |
| End-points | 6MWD, NYHA FC, survival, event-free survival | Survival, survival on monotherapy |
| Baseline CI L·min−1·m−2 | 2.13±0.66 | |
| Baseline 6MWD m | 305±11 | |
| NYHA FC II/III/IV % | 7/66/27 | 15/76/9 |
| Dose ng·kg−1·min−1 | 1 yr: 26 | 1 yr: 26 |
| 2 yrs: 32 | 2 yrs: 36 | |
| 3 yrs: 40 | 3 yrs: 42 | |
| 4 yrs: 42 | ||
| Age yrs | 49 (12–81) | 46 (5–84) |
Data are presented as mean±sd or mean (range), unless otherwise stated. CI: cardiac index; 6MWD: 6-min walk distance; NYHA: New York Heart Association; FC: functional class; PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension.